# A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)

> **NCT01230827** · PHASE3 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 173 (actual)

## Conditions studied

- Juvenile Idiopathic Arthritis

## Interventions

- **DRUG:** CNTO 148 (Golimumab)
- **DRUG:** Placebo
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT01230827
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-12
- **Primary completion:** 2013-09
- **Final completion:** 2014-05
- **Target enrollment:** 173 (ACTUAL)
- **Why stopped:** Trial has failed to meet primary - and major secondary endpoints
- **Last updated:** 2016-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01230827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01230827, "A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01230827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*